Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial

The goal of this clinical trial is to learn if adding rituximab to the ATG-based Protocol can prevent Epstein-Barr virus (EBV) from reactivating in children who have received an allogeneic haploidentical hematopoietic stem cell transplant. It will also learn about the safety of adding rituximab. The main questions it aims to answer are:
Does giving rituximab twice during the conditioning regimen lower the number of children who have EBV reactivation after transplant?
What medical problems or side effects do children experience when they receive rituximab in addition to the ATG-based Protocol?
Researchers will compare the group that receives rituximab (two doses before transplant) with a control group that receives no rituximab, to see if the addition of rituximab effectively prevents EBV reactivation.
Participants will:
Receive either rituximab (two doses during the preconditioning phase) or no extra treatment (control group), depending on which group they are assigned to
Have regular follow-up visits for blood tests to monitor their EBV-DNA levels
Keep a record of any symptoms or health changes they notice between visits

开始日期2026-07-01

申办/合作机构

南方医科大学南方医院

NCT05253495

/ Recruiting临床2期IIT

Reducing the Burden of Oncologic Chemoradiotherapy And Radiation Exposure From Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults With Lymphoma

The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).

开始日期2022-02-01

申办/合作机构

New York Medical College

NCT04671420

/ Withdrawn临床3期

A Phase 3 Multi-Centre, Randomised, Double-Blind, Parallel-Arm Study to Evaluate the Efficacy and Safety of HLX01 Versus Rituximab (Mabthera®) as First Line Treatment in Patients With Low Tumour Burden Follicular Lymphoma.

The study is a Phase 3 multi-centre, randomised, double-blind, parallel-arm study to evaluate the efficacy and safety of HLX01 versus European Union (EU)-sourced Mabthera® as first line treatment in patients with low tumour burden FL.
The study will consist of a Screening Period (up to 42 days), Treatment Period (Week 1 to Week 44/Month 11), and End of Study (EOS; Month 12 Visit). Approximately 212 patients (106 in each treatment group) will be enrolled.
Utilising a 1-sided 97.5% CI for the risk difference, a reference proportion of 83.2% for Mabthera®, delta for non-inferiority of -17%, and assuming a true difference of 1%, a sample size of 106 patients per arm (212 total) provides approximately 85% power to show non-inferiority of HLX01 to Mabthera® on a primary endpoint of risk difference in ORR up to Week 28. No dropout is included, as all patients will either have data provided for ORR (based on best response), or will be classed as non-responder.

开始日期2020-10-01

申办/合作机构

上海复宏汉霖生物技术股份有限公司

100 项与利妥昔单抗生物类似药（复宏汉霖）相关的临床结果

登录后查看更多信息

100 项与利妥昔单抗生物类似药（复宏汉霖）相关的转化医学

登录后查看更多信息

100 项与利妥昔单抗生物类似药（复宏汉霖）相关的专利（医药）

登录后查看更多信息

项与利妥昔单抗生物类似药（复宏汉霖）相关的文献（医药）

2026-02-01·Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience

Article

作者: Wu, Hanbiao ; Yang, Sensen ; Huang, Guoning ; Chen, Jisheng ; Chen, Haitao ; Yang, Changyuan ; Deng, Weishang

Introduction:

HLX01 is the first rituximab biosimilar produced in China and the first monoclonal antibody biosimilar marketed in China. The purpose of this study was to comprehensively evaluate whether HLX01 is clinically consistent with the original drug based on real-world data to provide evidence for the clinical substitution of biosimilars in China.

Methods:

A single-center retrospective study was conducted to select patients with diffuse large B-cell lymphoma who met the inclusion criteria and were treated with HLX01 or reference rituximab. Baseline characteristics, efficacy and safety results were recorded, and the corresponding statistical analysis was performed for various indicators.

Results:

Thirty-three patients diagnosed with diffuse large B-cell lymphoma were included and divided into two groups that received HLX01 or reference rituximab. The results showed no significant difference in the overall response rate (86.7% vs. 88.9%; p = 1.000) or complete response rate (46.7% vs. 55.6%; p = 0.889) between the two groups. Kaplan–Meier survival curves also showed no significant difference in time-to-event variables between the two groups (log-rank = 0.244). Safety was also comparable in both groups.

Conclusions:

HLX01 is a suitable replacement for reference rituximab in the treatment of diffuse large B-cell lymphoma and is relatively inexpensive, thereby reducing the economic burden of patients. Nevertheless, the conclusion of this study still needs to be further validated by large-sample real-world data and explored for HLX01 in other indications, such as follicular lymphoma.

Clinical trial registration:

Not applicable.

2022-12-01·Arthritis research & therapy

Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study

Article

作者: Pingting Yang ; Zhuoli Zhang ; Xiaoxia Yu ; Linjie Chen ; Lingyun Sun ; Hongsheng Sun ; Jiankang Hu ; Jun Zhu ; Hua Wei ; Jian Wu ; Huaxiang Liu ; Jian Xu ; Jianhong Zhao ; Ju Liu ; Xiaomei Li ; Qingyu Wang ; Lijun Wu ; Zhenyu Jiang ; Qinghua Zou ; Wufang Qi ; Xiaofeng Zeng ; Meimei Wang ; Xin Lu ; Xiumei Liu ; Fu-ai Lu ; Ying Li ; Rongbin Li ; Yang Li ; Hua Zhang ; Hao Zhang ; Liqi Bi ; Baijie Xu ; Cibo Huang ; Lan He ; Xiangping Liao ; Yi Liu ; Huaxiang Wu ; Jianzhao Cheng ; Xiaoxia Li ; Hongwei Du ; Fengju Li ; Zongwen Shuai ; Jingchun Jin

Abstract:

Background:

To evaluate the efficacy and safety of HLX01, a rituximab biosimilar, as combination therapy with methotrexate in Chinese patients with active rheumatoid arthritis who had inadequate responses to methotrexate.

Methods:

In this double-blind, placebo-controlled phase 3 trial, biologic-naïve patients with moderate-to-severe active rheumatoid arthritis and inadequate responses to methotrexate were randomized 2:1 to receive 1000 mg HLX01 or placebo intravenously on days 1 and 15. On the first day of weeks 24 and 26, patients in both groups received 1000 mg HLX01 via intravenous infusion. The primary endpoint was the American College of Rheumatology (ACR) 20 response rate at week 24. Secondary endpoints including efficacy, safety, immunogenicity, pharmacokinetics and pharmacodynamics were assessed up to week 48.

Results:

Between 28 May 2018 and 11 September 2020, 275 patients were randomized to the HLX01 group (n = 183) or the placebo group (n = 92). At week 24, the proportion of patients achieving ACR20 response was significantly greater in the HLX01 group compared with the placebo group in the intention-to-treat population (60.7% vs 35.9%; P < 0.001) and per-protocol set (60.3% vs 37.1%; P < 0.001). Most secondary efficacy endpoints favoured HLX01 when assessed at weeks 12, 24, 36 and 48. Incidences of treatment-emergent adverse events were similar between groups. Infusion-related reactions occurred more frequently following the initial two doses of HLX01 than the subsequent doses.

Conclusions:

HLX01 plus methotrexate improved clinical outcomes compared with placebo in Chinese patients with rheumatoid arthritis who had inadequate responses to methotrexate. This treatment regimen was well tolerated, showing comparable safety profiles to placebo.

Trial registration:

ClinicalTrials.gov, NCT03522415. Registered on 11 May 2018.

2021-04-01·Advances in therapy3区 · 医学

Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial

3区 · 医学

Article

作者: Zheng, Meifang ; Zhou, Hui ; Cai, Zhen ; Liu, Jing ; Zhou, Jianfeng ; Yao, Hongxia ; Yang, Wei ; Xiang, Ying ; Zhang, Qingyuan ; Lv, Fangfang ; Feng, Jifeng ; Lin, Jinying ; Wang, Huaqing ; Sang, Wei ; Cao, Yongqing ; Liu, Wei ; Zhang, Huilai ; Yang, Shun'e ; Shuang, Yuerong ; Zhou, Keshu ; Zeng, Shan ; Zhang, Hongyu ; Guo, Ye ; Ge, Zheng ; Feng, Ru ; Li, Wei ; Zhang, Mingzhi ; Xu, Hao ; Zou, Qingfeng ; Wang, Shuye ; Zhao, Hongguo ; Zou, Liqun ; Song, Yuqin ; Qiu, Lugui ; Liang, Aibin ; Du, Xin ; Wang, Lin ; Zhang, Xiaohong ; Zhang, Wei ; Zuo, Xuelan ; Shao, Zonghong ; Huang, Haiwen ; Liu, Peng ; Ma, Junxun ; Yu, Jie ; Ran, Wenhua ; Pang, Ying ; Li, Yan ; Sun, Xing ; Gao, Da ; Zhu, Jun ; Chen, Zhendong ; Xu, Wei ; Hou, Ming ; Xia, Ruixiang ; Liu, Lin

INTRODUCTION:

Patients with diffuse large B-cell lymphoma (DLBCL) have limited access to rituximab. IBI301 is a recombinant chimeric murine/human anti-CD20 monoclonal antibody and is a candidate biosimilar to rituximab. This study aimed to assess the therapeutic equivalence of IBI301 and rituximab in previously untreated patients with diffuse large B-cell lymphoma (DLBCL).

METHODS:

This multicenter, randomized, double-blind, parallel-group, phase 3 trial compared IBI301 and rituximab, both plus the chemotherapy of doxorubicin, cyclophosphamide, vindesine, and prednisone (CHOP), was conducted in 68 centers across China. Eligible patients with untreated CD20 positive (CD20⁺) DLBCL randomly received IBI301 (375 mg/m²) plus the standard CHOP or rituximab (375 mg/m²) plus the standard CHOP for six cycles of a 21-day cycle. The primary end point was the overall remission rate (ORR). Efficacy equivalence was defined if 95% CIs for the ORR difference between the two groups were within a ± 12.0% margin.

RESULTS:

Between August 22, 2016, and September 5, 2018, 419 patients were randomly allocated into the IBI301 group (N = 209) and rituximab group (N = 210). In the full analysis set, the ORR was 89.9% and 93.8% in the IBI301 and rituximab groups, respectively, and the ORR difference was -3.9% (95% CI - 9.1%-1.3%), falling within a ± 12.0% margin. The occurrences of treatment-emergent adverse events (TEAEs) (100% vs. 99.0%) and AEs of grade ≥ 3 (87.1% vs. 83.3%) were similar in the two groups (P > 0.05).

CONCLUSIONS:

IBI301 had a non-inferiority efficacy and a comparable safety compared with rituximab. IBI301 plus CHOP could be suggested as a candidate treatment regimen for untreated patients with CD20⁺ DLBCL.

TRIAL REGISTRATION:

This trial is registered on ClinicalTrials.gov (NCT02867566).

742

项与利妥昔单抗生物类似药（复宏汉霖）相关的新闻（医药）

2026-07-14

·复星医药

星融周报 | 持续推进全球化人才培养，多款产品纳入2026版国家基药目录

01 一场跨越中印的双向奔赴｜复星医药启动全球人才和技术交流项目 2026年7月3日下午，复星医药与印度子公司Gland Pharma的人才和技术交流项目（TTE）启动仪式于集团总部举行。复星医药联席总裁、成熟产品及制造事业部首席执行官李静，复星医药总裁助理、成熟产品及制造事业部高级副总裁兼CHO周勇，与8名中印技术骨干共同参与和见证项目启动仪式。未来三个月，这批来自研发、生产、质量领域的核心人才将分赴两地，开展双向驻场交流，以技术共享、人才共育打通中印成熟制剂业务的知识壁垒，以常态化全球人才交流为打造中国本土跨国药企（C-MNC）持续注入人才动能。一场跨越中印的双向奔赴｜复星医药启动全球人才和技术交流项目 02 复星医药成员企业桂林南药携手复星基金会等爱心伙伴驰援广西防洪救灾 7月6日以来，受“美莎克”台风降雨影响，广西南宁、贵港市部分地区水库出现险情，造成较大范围内群众受灾。上海复星公益基金会（下称“复星基金会”）第一时间开启驰援工作，携手多方联合捐赠应急物资支持防洪救灾，并派出两位同事在南宁前线指挥部协助相关救援工作。8日，复星医药成员企业桂林南药宣布携手复星基金会和广西慈善联合总会开展紧急驰援，捐赠20万元爱心款项用于支持防汛救灾及后续重建工作。复星医药成员企业桂林南药携手复星基金会等爱心伙伴驰援广西防洪救灾 03 全球研发｜复星医药子公司复宏汉霖PD-L1xVEGF双抗HLX37新增临床批准，加速下一代IO联合化疗/ADC布局 2026年7月10日，复星医药子公司复宏汉霖（2696.HK）宣布，公司自研的HLX37（重组人源化抗PD-L1与VEGF双特异性抗体）单药及联合化疗或创新型程序性死亡-配体1（PD-L1）抗体偶联药物（ADC）注射用HLX43用于晚期/转移性实体瘤治疗的I期临床研究获中国国家药品监督管理局（NMPA）批准。该分子探索晚期/转移性实体瘤治疗的I期临床研究正在同步进行中。 04 复星医药子公司复宏汉霖4款核心产品纳入2026版国家基药目录，持续提升优质生物药可及性 2026年7月9日，国家卫生健康委、国家中医药局、国家疾控局三部门联合发布《国家基本药物目录（2026年版）》（以下简称“基药目录”），该目录将于2026年9月1日起正式实施。复星医药子公司复宏汉霖自主开发和生产的汉曲优®（曲妥珠单抗，美国商品名：HERCESSI™，欧洲商品名：Zercepac®）、汉贝泰®（贝伐珠单抗）、汉利康®（利妥昔单抗）和汉达远®（阿达木单抗）4款产品6个规格被纳入，覆盖抗肿瘤及自身免疫疾病治疗领域。此次纳入不仅是对公司产品临床价值与品质实力的高度认可和权威背书，也将有力提升高品质生物药在全国各级医疗机构的可及性，切实惠及国内广大患者。复星医药子公司复宏汉霖4款核心产品纳入2026版国家基药目录，持续提升优质生物药可及性 05 HTAi 2026 | 张璐莹教授：阿基仑赛注射液成本效用分析重磅公布，CAR-T疗法重塑淋巴瘤价值评估新格局近年来，嵌合抗原受体T细胞（CAR-T）疗法阿基仑赛注射液（Axicabtagene Ciloleucel）在血液肿瘤领域引起了持续关注。作为国内首个获批的CAR-T产品，其适应证已扩展至复发或难治性大B细胞淋巴瘤（R/R LBCL）的二线治疗。显著提升的缓解率和生存获益，伴随高昂的单次治疗费用，使“物有所值”成为各方聚焦的核心议题。近期，复旦大学公共卫生学院张璐莹教授团队从中国医疗卫生体系视角出发，完成了一项严谨的成本效用分析，通过长期模型模拟给出了量化答案。该成果于国际卫生技术评估协会2026年学术年会（HTAi 2026）以口头报告形式公布。 HTAi 2026 | 张璐莹教授：阿基仑赛注射液成本效用分析重磅公布，CAR-T疗法重塑淋巴瘤价值评估新格局联系方式媒体：pr@fosunpharma.com 投资人：ir@fosunpharma.com

2026-07-13

·中国医药创新促进会

歌礼向FDA递交两项治疗肥胖症的IND|2026年版国家基本药物目录公布

新药审批歌礼制药ASC36 ASC35 7月6日，歌礼制药宣布，近期已向美国食品药品监督管理局（FDA）递交了两项新药临床试验申请（IND）：每月一次至每季度一次新一代多肽胰淀素受体激动剂ASC36，以及ASC36_35 FDC，即ASC36联合多肽GLP-1R/GIPR激动剂ASC35的每月一次注射复方制剂，用于治疗肥胖症。荣昌生物泰它西普 7月9日，国家卫生健康委、国家中医药局、国家疾控局三部门联合发布《国家基本药物目录（2026年版）》，荣昌生物自主研发的全球首创BLyS/APRIL双靶点新型融合蛋白药物泰它西普（注射用无菌粉末：80mg）被纳入目录内的“免疫系统用药”。先声药业依达拉奉右莰醇注射用浓溶液先声药业自主研发的国家1类新药先必新®（依达拉奉右莰醇注射用浓溶液）被正式纳入新版国家基本药物目录。君实生物阿达木单抗君实生物宣布，君迈康®（阿达木单抗注射液）被纳入新版国家基本药物目录，持续惠及类风湿关节炎、强直性脊柱炎、银屑病等自身免疫性慢病患者。复宏汉霖曲妥珠单抗贝伐珠单抗利妥昔单抗阿达木单抗 HLX37 复宏汉霖自主开发和生产的汉曲优®（曲妥珠单抗）、汉贝泰®（贝伐珠单抗）、汉利康®（利妥昔单抗）和汉达远®（阿达木单抗）4款产品6个规格被纳入，覆盖抗肿瘤及自身免疫疾病治疗领域君迈康®（阿达木单抗注射液）被纳入新版国家基本药物目录，持续惠及类风湿关节炎、强直性脊柱炎、银屑病等自身免疫性慢病患者。 7月10日，复宏汉霖宣布，公司自研的HLX37（重组人源化抗PD-L1与VEGF双特异性抗体）单药及联合化疗或创新型程序性死亡-配体1（PD-L1）抗体偶联药物（ADC）注射用HLX43用于晚期/转移性实体瘤治疗的I期临床研究获中国国家药品监督管理局（NMPA）批准。甘李药业 GLR2038片 7月10日，甘李药业宣布，其自主研发、拥有独立知识产权的1类化学新药蛋白降解靶向嵌合体（PROTAC）雌激素受体（ER）降解剂GLR2038片，已正式获得中国国家药品监督管理局（NMPA）临床试验批准。该药物拟用于治疗晚期乳腺癌。研发进展诺诚健华 ICP-B208 7月6日，诺诚健华宣布，公司自主研发的靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药。基于诺诚健华自主研发的ADC技术平台，ICP-B208由人源化抗CDH17抗体通过蛋白酶可裂解连接子与公司自主开发的强效有效载荷偶联而成，可精准靶向肿瘤细胞，同时最大限度减少脱靶效应。恒瑞医药 HRS-7535 7月7日，恒瑞医药宣布，口服小分子GLP-1受体激动剂HRS-7535在中国成人肥胖及超重人群中的3期临床试验（HARBOR-1）取得积极顶线数据。HRS-7535 所有剂量组（120 mg、180 mg）在治疗44周时达到了所有主要终点和关键次要终点；且继续治疗减重效果持续，第50周时180 mg组平均减重可达11.1%；同时观察到了多项心血管代谢指标的改善。合作 7月6日，华领医药宣布，华领医药与香港生物科技企业GemVCare（简称GVC）达成科研合作协议，双方将依托各自核心优势，围绕公司核心产品——全球首创抗糖尿病新药葡萄糖激酶激活剂(GKA)多格列艾汀以及GVC的精准诊断技术，开展精准糖尿病管理真实世界临床研究协作，以完善该药在香港本地循证医学的临床应用。 7月8日，中国生物制药有限公司宣布，本集团附属公司正大天晴已与阿斯利康就本集团自主研发的PDE3/4抑制剂订立独家授权协议。根据协议条款，本集团将授予阿斯利康在中国以外地区开发、生产及商业化TQC3721的独家许可。阿斯利康还将获得TQC3721特定开发方案的全球独家许可。本集团有权获得2亿美元的首付款，以及潜在开发、监管及销售里程碑付款，合计最高可达19亿美元,同时还将获得基于TQC3721年度净销售额的最高可达双位数百分比的分级特许权使用费。协议的生效以惯常的交割条件为前提，包括取得相关监管部门的批准。 7月10日，先声药业宣布，已于近日与美国薛定谔公司达成全球药物发现与开发合作协议。双方将充分发挥各自在药物研发领域的优势，聚焦未满足的临床需求，依托先声药业在相关治疗领域的专业积累，共同推进创新药物研发。 ●会员动态6月29日-7月5日 ●会员动态6月22日-6月28日 ●会员动态6月15日-6月21日 ●会员动态6月1日-6月7日 END

抗体药物偶联物ASCO会议蛋白降解靶向嵌合体临床申请申请上市

2026-07-11

·百度百家

聚焦主业商业向善｜复星周报20260711

来源：复星 1 复星旅文与重庆北碚区达成战略合作协议将携手打造高品质文旅综合体 7月8日，复星旅文与重庆市缙云山北碚片区管理委员会、重庆市城市建设土地发展有限责任公司以及重庆北碚文旅产业发展有限公司，在上海BFC外滩金融中心共同签订了“北碚缙云山北温泉康养片区城市更新综合开发战略合作框架协议书”。复星国际联席CEO徐晓亮表示，这是复星旅文打造HiSphere重庆超级文旅Mall之后，在重庆推进的又一个全新文旅项目，将携手各方助力北碚打造出独具文化特色的文旅康养综合体。 2 商业向善复星基金会携手爱心伙伴驰援广西抗洪救灾 7月6日以来，受“美莎克”台风降雨影响，广西南宁、贵港市部分地区水库出现险情，造成较大范围内群众受灾。上海复星公益基金会第一时间开启驰援工作，携手多方联合捐赠应急物资支持防洪救灾，并派出两位同事在南宁前线指挥部协助相关救援工作。8日，复星医药成员企业桂林南药宣布携手复星基金会和广西慈善联合总会开展紧急驰援，捐赠20万元爱心款项用于支持防汛救灾及后续重建工作。截至10日，已有近60万件物资从上海复星公益基金会的驰援行动中陆续送抵前方，在当地政府的统一协调下分批发放至救援队和受灾群众手上。后续，复星基金会将密切关注一线灾情和有关物资需求。左右滑动查看 3 复宏汉霖4款核心产品纳入2026版国家基药目录持续提升优质生物药可及性 7月9日，复宏汉霖自主开发和生产的汉曲优、汉贝泰、汉利康和汉达远共4款产品6个规格被纳入国家卫生健康委、国家中医药局、国家疾控局三部门联合发布《国家基本药物目录（2026年版）》，该目录将于2026年9月1日起正式实施。国家基本药物目录是各级医疗卫生机构配备使用药品的依据。此次纳入不仅是对公司产品临床价值与品质实力的高度认可和权威背书，也将有力提升高品质生物药在全国各级医疗机构的可及性，切实惠及国内广大患者。一周快讯近日，复宏汉霖自主研发的抗PD-1单抗汉斯状用于一线治疗晚期非鳞状非小细胞肺癌（nsqNSCLC）的III期临床研究最终分析结果正式发表于国际顶尖肿瘤期刊Cancer Communications。研究结果显示，斯鲁利单抗联合化疗组的中位总生存期（mOS）达到26.8个月。近日，健嘉医疗联动复星联合光辉岁月护理保险（长青3.0版），深度打造“保险+医疗”协同生态。依托双方合作体系，保单持有者可一键解锁健嘉医疗专属疾病康护全流程服务，实现院前、院中、院后闭环式康复管理。 7月11日至8月15日，三亚亚特兰蒂斯水世界音乐节正式开唱。每周六19点，从校园民谣到华语经典，从人气国风到热血摇滚多名实力音乐人轮番登场。 //////// 第三百一十六期周报汇报完毕，下周继续做对的事，做难的事，做需要时间积累的事！让全球家庭生活更幸福！

100 项与利妥昔单抗生物类似药（复宏汉霖）相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC02	DB00073

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
类风湿关节炎	中国	上海复宏汉霖生物制药有限公司	2022-02-23
类风湿关节炎	中国	上海复宏汉霖生物技术股份有限公司	2022-02-23
淋巴细胞白血病	中国	上海复宏汉霖生物制药有限公司	2020-07-14
弥漫性大B细胞淋巴瘤	中国	上海复宏汉霖生物制药有限公司	2019-02-22
滤泡性淋巴瘤	中国	上海复宏汉霖生物制药有限公司	2019-02-22
非霍奇金淋巴瘤	中国	上海复宏汉霖生物制药有限公司	2019-02-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
CD20阳性滤泡性淋巴瘤	临床3期	-	上海复宏汉霖生物技术股份有限公司	2020-10-01
复发性滤泡性淋巴瘤	临床3期	-	上海复宏汉霖生物技术股份有限公司	2020-10-01
CD20阳性弥漫性大B细胞淋巴瘤	临床3期	中国	上海复宏汉霖生物技术股份有限公司	2015-10-01
CD20阳性B细胞淋巴瘤	临床2期	-	上海复宏汉霖生物技术股份有限公司	2014-10-01
CD20阳性的B细胞非霍奇金淋巴瘤	临床1期	中国	上海复宏汉霖生物技术股份有限公司	2015-06-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed 人工标引	N/A	弥漫性大B细胞淋巴瘤	33	Rituximab-HLX01	糧築鬱廠鑰襯觸襯鹽憲(選膚網壓範壓淵構鏇艱) = 構艱糧鹽遞選壓繭鏇艱製製夢遞觸選鹹鬱齋積 (餘觸蓋遞繭簾範餘廠齋 ) 更多	相似	2022-07-03
				Rituximab	糧築鬱廠鑰襯觸襯鹽憲(選膚網壓範壓淵構鏇艱) = 醖鬱簾鏇鏇衊鬱選鏇壓製製夢遞觸選鹹鬱齋積 (餘觸蓋遞繭簾範餘廠齋 ) 更多
NCT03522415 (Pubmed) 人工标引	临床3期	类风湿关节炎	275	methotrexate+HLX01	遞製淵積簾壓鹽廠艱蓋(衊願選簾淵醖觸網繭壓) = 願顧醖蓋憲憲製襯艱遞遞簾鏇蓋製艱網鏇襯鬱 (餘築餘簾遞選選膚積選 ) 更多	积极	2022-06-10
				methotrexate+Placebo	遞製淵積簾壓鹽廠艱蓋(衊願選簾淵醖觸網繭壓) = 鹽醖鬱衊窪遞醖襯衊構遞簾鏇蓋製艱網鏇襯鬱 (餘築餘簾遞選選膚積選 ) 更多
NCT02787239 (HLX01-NHL03, Pubmed \| J Hematol Oncol) 人工标引	临床3期	CD20阳性弥漫性大B细胞淋巴瘤一线 CD20 Positive	407	CHOP+HLX01	積觸網範餘構淵餘膚積(衊顧獵構鑰艱窪範衊築) = 願憲窪網網鹽餘憲鬱簾顧憲遞鏇網糧壓壓製構 (夢餘襯構築夢築鏇衊廠 ) 更多	相似	2020-04-16
				CHOP+Rituximab	積觸網範餘構淵餘膚積(衊顧獵構鑰艱窪範衊築) = 鑰顧網願範願網餘憲壓顧憲遞鏇網糧壓壓製構 (夢餘襯構築夢築鏇衊廠 ) 更多
NCT03355872 (HLX01-RA01, ESMO_ASIA2019)	临床1/2期	弥漫性大B细胞淋巴瘤	196	HLX01	蓋積鹹選製憲憲觸蓋窪(遞選壓鏇鏇艱壓簾淵糧) = 願憲願獵遞網廠製衊鹹鬱鹹齋鹹顧獵淵網繭糧 (鑰壓築鏇積鹽憲憲壓鹽 ) 更多	-	2019-11-24